ReLearn is a startup focused on leveraging artificial intelligence to assist companies and municipalities in minimizing their environmental impact by monitoring waste production. Utilizing a plug-and-play sensor called NANDO, which is installed on trash bins, ReLearn gathers precise data on the quantity and quality of waste generated daily. This data facilitates the creation of detailed sustainability reports and enhances awareness of environmental issues among corporate and civic stakeholders. The company employs gamification techniques to engage users and promote environmentally responsible behaviors. ReLearn aims to support visionary organizations in achieving their ZERO WASTE goals and adhering to key Sustainable Development Goals. By transforming ordinary bins into smart waste management systems, ReLearn enables clients to automate processes and improve efficiency while reducing carbon emissions and operational costs associated with improper waste disposal. The company has garnered recognition for its innovative approach, being a winner of the European Social Innovation Competition in 2022.
Releaf Paper is a producer of sustainable paper products from fallen leaves. They work on the task of finding a solution to achieve sustainability in the production of paper using new raw materials - fallen leaves, instead of wood.
Restore Medical develops and provides a device-based therapy for congestive heart failure. It improves patient quality of life and reduce hospital readmission rates. Restore Medical's product, ContraBand, is a novel catheter-delivered implant in the pulmonary arteries for treatment of left ventricle failure, for patients with preserved right ventricle function. Restore Medical was founded in 2016 and is headquartered in Or Yehuda, Israel.
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an AI-powered patrol drone tailored for indoor security and inspection purposes. The company leverages artificial intelligence to create an autonomous indoor intelligence platform that enhances decision-making and reduces errors. Tando is capable of conducting security patrols, inspecting facilities, and identifying irregularities such as leaks and fire hazards. Additionally, the drone learns its environment and adapts its responses to various detected anomalies, thus improving area coverage and response times for users.
QuantrolOx specializes in developing automated machine learning-based control software for quantum technologies, focusing on the tuning, stabilization, and optimization of qubits. By providing robust software solutions, the company aids quantum scientists in achieving stable platforms for experimentation, which enhances the effectiveness of quantum computing applications. This innovative approach allows clients to utilize more cost-effective quantum infrastructure while efficiently implementing standard quantum computing technologies in their operations.
Developer of thin optical film technology designed to improve the user experience and safety while viewing digital displays. The company is engaged in developing technology and products that improve the user experience and safety while viewing digital displays, such as mobile phones, tablets, and control monitors, providing users with better experience and safety.
Aviwell is focused on creating healthy, natural, and sustainable solutions aimed at enhancing animal health and growth, thereby contributing to global nourishment. The company operates a microbiota-based discovery platform that leverages artificial intelligence and machine learning to bridge digital and life sciences. By developing innovative food products, Aviwell seeks to provide valuable insights into animal health, growth, and performance, ultimately supporting the agri-food industry in its efforts to sustainably meet the needs of a growing population.
Genetika+ is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
EZMEMS is an automation technology platform for smart plastic AIoT sensors.
Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.
GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.
Filterlex Medical Ltd. is a medical device startup based in Yokneam, Israel, focused on developing innovative solutions in the cardiovascular field. Established in 2015, the company is dedicated to creating advanced embolic protection devices aimed at minimizing the risk of stroke and other complications during catheter-based structural heart procedures. Their flagship device, CAPTIS, is designed for intuitive deployment and retrieval, providing full-body embolic protection by effectively deflecting, capturing, and removing embolic particles. The development of Filterlex's technology is rooted in a comprehensive understanding of existing products' limitations, addressing unmet needs within the medical community. The company is currently seeking seed funding to further advance its mission.
VBL Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and immune-inflammatory diseases. Founded to address significant unmet medical needs, the company focuses on creating therapies that surpass the limitations of currently available options. Its clinical pipeline is built on two proprietary platform technologies that utilize the body’s natural physiological and genetic regulatory mechanisms. The lead candidate, VB-111, is a gene-based biologic targeting solid tumors, specifically for recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also advancing a program aimed at anti-inflammatory diseases, leveraging its Lecinoxoid platform technology.
BELKIN Laser Ltd. is an innovative company based in Yavne, Israel, founded in 2013, that focuses on developing a groundbreaking one-second laser device for the treatment of glaucoma. This automated device aims to provide ophthalmologists with a means to deliver drop-less and contactless care, addressing the significant disparity between the large number of glaucoma patients, estimated at 67 million, and the relatively limited number of ophthalmologists available. The technology is particularly relevant for Open Angle Glaucoma, which affects 70% of glaucoma patients, and has the potential to pioneer treatment for Angle Closure Glaucoma, notably prevalent among Asian populations. BELKIN's solution is designed to be non-invasive, instantaneous, and painless, offering a patient-friendly alternative to traditional methods. By simplifying the treatment process, BELKIN Laser seeks to transform glaucoma care from a specialized procedure to a widely accessible option that can be performed by all ophthalmologists and healthcare providers, thereby enhancing patient access to essential care.
VBL Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and immune-inflammatory diseases. Founded to address significant unmet medical needs, the company focuses on creating therapies that surpass the limitations of currently available options. Its clinical pipeline is built on two proprietary platform technologies that utilize the body’s natural physiological and genetic regulatory mechanisms. The lead candidate, VB-111, is a gene-based biologic targeting solid tumors, specifically for recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also advancing a program aimed at anti-inflammatory diseases, leveraging its Lecinoxoid platform technology.
Wi-Charge is a company focused on solving the challenge of frequent recharging for mobile devices by utilizing proprietary wireless power transmission technology. Founded in 2010 and based in Rehovot Science Park, Israel, the company develops remote charging solutions that allow devices to recharge autonomously, requiring only 1-2 hours of charging per day to maintain continuous operation. This technology enables electronic devices such as cell phones, laptops, and various sensors to charge without user intervention, creating an experience akin to having an endless battery. Wi-Charge is currently in the process of commercializing its technology, with initial product launches anticipated within the next 12-18 months.
MYSPHERA SL specializes in providing innovative location and process visibility solutions for the healthcare sector through the Internet of Things (IoT) and real-time location systems (RTLS). Founded in 2012 and based in Paterna, Spain, the company develops a range of IoT devices and applications designed to enhance patient care and resource management in acute care hospitals, senior living facilities, and patient homes. Its offerings include tracking devices, alert systems, and environmental sensors, along with web applications such as MYHOSPITAL, MYNURSING, and MYLOCS, which assist healthcare providers in managing services effectively. MYSPHERA's solutions aim to improve patient outcomes and operational efficiency by delivering actionable information to clinicians, patients, and healthcare management across Europe, the Middle East, and Latin America.
Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, established in 2010. It specializes in developing innovative technology aimed at improving outcomes in colorectal surgeries. The company has created a proprietary, single-use intraluminal bypass device designed to minimize the risk of anastomotic leaks following intestinal surgery, particularly in patients with severe inflammatory bowel diseases or colorectal cancer. This device helps reduce contact between fecal matter and the anastomotic site, thereby decreasing the likelihood of complications that could lead to prolonged hospitalization or the need for additional surgeries. By offering a temporary alternative to diverting colostomies, Colospan's products aim to enhance patient recovery while maintaining overall well-being and safety during the post-operative period.
MYSPHERA SL specializes in providing innovative location and process visibility solutions for the healthcare sector through the Internet of Things (IoT) and real-time location systems (RTLS). Founded in 2012 and based in Paterna, Spain, the company develops a range of IoT devices and applications designed to enhance patient care and resource management in acute care hospitals, senior living facilities, and patient homes. Its offerings include tracking devices, alert systems, and environmental sensors, along with web applications such as MYHOSPITAL, MYNURSING, and MYLOCS, which assist healthcare providers in managing services effectively. MYSPHERA's solutions aim to improve patient outcomes and operational efficiency by delivering actionable information to clinicians, patients, and healthcare management across Europe, the Middle East, and Latin America.
Producer of food ingredients intended to provide upcycled ingredients for nutrition. The company's fermentation platform transforms wasted fruit and vegetable by-products into low-carb flour with improved nutritional value and functionality, enabling clients to get flour that is high in protein and dietary fiber, while being low in starch, sugars, and fats.
Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an AI-powered patrol drone tailored for indoor security and inspection purposes. The company leverages artificial intelligence to create an autonomous indoor intelligence platform that enhances decision-making and reduces errors. Tando is capable of conducting security patrols, inspecting facilities, and identifying irregularities such as leaks and fire hazards. Additionally, the drone learns its environment and adapts its responses to various detected anomalies, thus improving area coverage and response times for users.
NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, particularly focusing on conditions like chronic obstructive pulmonary disease (COPD) and asthma. The company has created a nanosensor-based wearable device that detects subtle changes in a patient's respiratory condition, allowing for early identification and intervention at home. This proactive approach aims to improve patient outcomes by enabling healthcare professionals to address respiratory deteriorations before they reach critical stages, thereby reducing the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation is committed to enhancing the management of chronic respiratory conditions through innovative technology.
Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.
Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.
The ZygoFix is a medical device company.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Developer of non-invasive inhalers designed for the treatment of respiratory disorders. The company's device generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, creating multiple momentary dilating forces that gently pry open the collapsed airways, enabling doctors to treat chronic obstructive pulmonary disease by smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.
Developer of non-invasive inhalers designed for the treatment of respiratory disorders. The company's device generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, creating multiple momentary dilating forces that gently pry open the collapsed airways, enabling doctors to treat chronic obstructive pulmonary disease by smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
EyeFree Assistive Communication has developed EyeControl, an assistive communication device designed for ALS and other "locked-in" patients, including patients admitted into ICU departments which may be temporarily "locked-in" due to medical procedures or being connected to devices which don't enable communication. EyeControl is wearable, enabling 24/7 communication; affordable, so that any patient will have access to the device and simple to use, requiring dramatically lower training time than existing devices (as proven in a clinical trial). The device enables communication ranging from a call for help to a full conversation and it can be connected to other devices via Bluetooth. The user has the option to transmit a different language to the output speaker, allowing communication with a caregiver that may speak a different language.
Evoy AS designs and manufactures electric propulsion boat systems. The company offers marine electric propulsion systems, including inboard electric propulsion, outboard electric propulsion, and battery modules and ranges for the elimination of global boating emissions. It also offers Evoy ecosystem, which provides climate control, real-time motor data, smart battery management, data dashboard visualization, online connection, automatic identification system, port change capabilities, first stage automation, and assistance services. The company serves boat manufacturing industries. The company was founded in 2018 and is headquartered in Florø, Norway.
VoltAero is a manufacturer of electric aircraft that focuses on providing safe, quiet, and eco-friendly flight solutions. The company specializes in parallel electric-hybrid propulsion systems, allowing for efficient and reliable general aviation platforms. Its aircraft cater to a variety of uses, including private ownership, air taxi and charter services, and commercial flights for regional travel. By developing innovative electric aircraft, VoltAero aims to enable clients to embrace a new era of sustainable aviation.
Operator of an online medical platform intended to help doctors by making informed decisions around clinical diagnosis. The company's platform catalogs clinical information from peer-reviewed medical literature and utilizes artificial intelligence diagnostic engines to extract relevant insights, enabling doctors to map clinical knowledge for fast and informed clinical decision-making.
Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.
Clarifruit is transforming the fresh produce supply chain by offering an automated quality control and data analytics platform that addresses significant waste issues in the industry. With approximately 45% of fresh produce wasted due to inconsistent quality standards and decision-making processes, Clarifruit's solution utilizes artificial intelligence and proprietary computer vision technology to assess the external and internal attributes of produce in real time. This platform enhances productivity by tripling inspection efficiency and provides objective, consistent quality assessments. By enabling growers, wholesalers, and retailers to make informed, data-driven decisions, Clarifruit helps align the quality of fresh produce with customer demand, thereby reducing waste and maximizing profitability within the $2 trillion market.
MeMed Diagnostics Ltd. is a personalized diagnostics company established in 2009 and based in Tirat Carmel, Israel. The firm specializes in developing diagnostic solutions that focus on distinguishing between bacterial and viral infections to enhance patient care and reduce healthcare costs. Its flagship product, MeMed BV, is a test that analyzes patients' immune responses to differentiate between infection types. Additionally, the ImmunoDx platform combines proprietary biomarkers and algorithms to provide rapid and actionable insights for healthcare professionals, thereby addressing the challenge of antibiotic misuse, which is prevalent in healthcare systems worldwide. By accurately identifying the source of infection, MeMed's diagnostics aim to prevent inappropriate antibiotic prescriptions, mitigate the emergence of resistant bacterial strains, and ultimately improve treatment outcomes for infectious diseases.
Trisol Medical Ltd is a company based in Yokneam, Israel, that specializes in the development of transcatheter tricuspid replacement valves. Established in 2016, it focuses on innovative solutions in the field of cardiac interventions, specifically targeting the treatment of tricuspid valve diseases. As a portfolio company, Trisol Medical is positioned within the medical technology sector, aiming to enhance patient outcomes through its advanced valve replacement technologies.
Trisol Medical Ltd is a company based in Yokneam, Israel, that specializes in the development of transcatheter tricuspid replacement valves. Established in 2016, it focuses on innovative solutions in the field of cardiac interventions, specifically targeting the treatment of tricuspid valve diseases. As a portfolio company, Trisol Medical is positioned within the medical technology sector, aiming to enhance patient outcomes through its advanced valve replacement technologies.
NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, particularly focusing on conditions like chronic obstructive pulmonary disease (COPD) and asthma. The company has created a nanosensor-based wearable device that detects subtle changes in a patient's respiratory condition, allowing for early identification and intervention at home. This proactive approach aims to improve patient outcomes by enabling healthcare professionals to address respiratory deteriorations before they reach critical stages, thereby reducing the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation is committed to enhancing the management of chronic respiratory conditions through innovative technology.
VayaVision Sensing Ltd. is a technology company that specializes in developing perception engine software aimed at enhancing the safety and efficiency of autonomous driving. Founded in 2016 and headquartered in Or Yehuda, Israel, the company offers VAYA-Drive, an artificial intelligence cognition platform that integrates raw data fusion with advanced computer vision techniques. This platform generates comprehensive environmental models, enabling critical functions such as road and free space detection, lane detection, object detection and tracking, and recognition of traffic signs. By utilizing deep learning algorithms, VayaVision delivers a reliable detection and classification system that accurately assesses the size, shape, and velocity of surrounding objects, including small obstacles. This innovative approach not only improves sensing capabilities for autonomous vehicles but also contributes to cost reductions within the automotive industry. Since July 2020, VayaVision has operated as a subsidiary of LeddarTech Inc.